Search Result

Results for "

Gastroesophageal

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) ADC Antibody (1) Apoptosis (10) Bacterial (22) Calcium Channel (3) CD3 (1) Cholecystokinin Receptor (1) Cholinesterase (ChE) (4) Claudin (2) Cytochrome P450 (1) Dopamine Receptor (7) Drug Derivative (3) Drug Intermediate (1) Drug Metabolite (5) EGFR (1) Exosomes (4) GABA Receptor (4) Histamine Receptor (7) Isotope-Labeled Compounds (15) mGluR (4) Neurokinin Receptor (1) PD-1/PD-L1 (2) Prostaglandin Receptor (1) Proton Pump (38) Reference Standards (13) Trk Receptor (3) VEGFR (1)
By Research Areas:	Cancer (37) Cardiovascular Disease (1) Endocrinology (20) Infection (1) Inflammation/Immunology (32) Metabolic Disease (16) Neurological Disease (11)

By Targets:

5-HT Receptor (4)

ADC Antibody (1)

Apoptosis (10)

Bacterial (22)

Calcium Channel (3)

CD3 (1)

Cholecystokinin Receptor (1)

Cholinesterase (ChE) (4)

Claudin (2)

Cytochrome P450 (1)

Dopamine Receptor (7)

Drug Derivative (3)

Drug Intermediate (1)

Drug Metabolite (5)

EGFR (1)

Exosomes (4)

GABA Receptor (4)

Histamine Receptor (7)

Isotope-Labeled Compounds (15)

mGluR (4)

Neurokinin Receptor (1)

PD-1/PD-L1 (2)

Prostaglandin Receptor (1)

Proton Pump (38)

Reference Standards (13)

Trk Receptor (3)

VEGFR (1)

By Research Areas:

Cancer (37)

Cardiovascular Disease (1)

Endocrinology (20)

Infection (1)

Inflammation/Immunology (32)

Metabolic Disease (16)

Neurological Disease (11)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17021

Esomeprazole 3 Publications Verification (S)-Omeprazole; (-)-Omeprazole	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-15295

Vonoprazan Fumarate Maximum Cited Publications 6 Publications Verification TAK-438	Proton Pump	Metabolic Disease Cancer
Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-100007

Vonoprazan Maximum Cited Publications 6 Publications Verification TAK-438 free base	Proton Pump Bacterial	Endocrinology Cancer
Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .

HY-B0656

Rabeprazole 5 Publications Verification LY307640	Proton Pump Apoptosis Bacterial	Inflammation/Immunology Cancer
Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-17022

Esomeprazole magnesium trihydrate 1 Publications Verification (S)-Omeprazole magnesium trihydrate; (-)-Omeprazole magnesium trihydrate	Exosomes Proton Pump	Endocrinology Cancer
Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent and orally active H ⁺, K ⁺-ATPase inhibitor. Esomeprazole magnesium trihydrate has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases .

HY-17023

Esomeprazole sodium 2 Publications Verification (S)-Omeprazole sodium; (-)-Omeprazole sodium	Exosomes Proton Pump Bacterial	Endocrinology Cancer
Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0656A

Rabeprazole sodium 5 Publications Verification LY307640 sodium	Proton Pump Apoptosis Bacterial	Inflammation/Immunology Cancer
Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B1446

Esomeprazole magnesium 2 Publications Verification (S)-Omeprazole magnesium; (-)-Omeprazole magnesium	Exosomes Proton Pump	Endocrinology Cancer
Esomeprazole magnesium ((S)-Omeprazole magnesium) is a potent and orally active H ⁺, K ⁺-ATPase inhibitor. Esomeprazole magnesium has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases .

HY-B0732

Itopride hydrochloride HSR803	Cholinesterase (ChE) Dopamine Receptor Bacterial	Neurological Disease
Itopride (HSR803) hydrochloride is a potent dopamine-2 antagonist and an acetylcholine esterase (AChE) inhibitor. Itopride hydrochloride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions, can be used as a gastrointestinal prokinetic agent. Itopride can be used for researching gastro-esophageal reflux disease (GERD) .

HY-P99437

Anbenitamab 1 Publications Verification KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .

HY-P991564

Arcotatug IBI-343 antibody; HB37A6; TAK-921 Antibody	ADC Antibody Claudin	Cancer
Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs .

HY-B0160

Lafutidine FRG-8813	Histamine Receptor	Metabolic Disease Endocrinology
Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H₂RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease .

HY-139557

Zastaprazan JP-1366	Proton Pump	Inflammation/Immunology
Zastaprazan (JP-1366) is a proton pump inhibitor and a potent potassium-competitive acid blocker. Zastaprazan can be used in the research of gastrointestinal inflammatory diseases or gastric acid-related diseases such as gastroesophageal reflux disease .

HY-139557A

Zastaprazan citrate JP-1366 citrate	Proton Pump	Inflammation/Immunology
Zastaprazan (JP-1366) citrate is a Proton pump inhibitor and potent potassium-competitive acid blocker. Zastaprazan citrate can be used in the research of gastrointestinal inflammatory diseases or gastric acid-related diseases such as gastroesophageal reflux disease .

HY-B0310

Nizatidine 2 Publications Verification	Histamine Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Nizatidine is a potent and orally active histamine H₂ receptor antagonist, can be used for the research of stomach and intestines ulcers. Nizatidine works by decreasing the secretion of gastric acid the stomach makes and prevent ulcers from coming back after they have healed in animal models .

HY-P99941

Retifanlimab INCMGA-00012; MGA-012	PD-1/PD-L1	Cancer
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .

HY-P99523

Vepsitamab AMG 199	CD3	Cancer
Vepsitamab (AMG 199) is a bispecific T-cell engager (HLE BiTE) that binds to MUC17 and CD3. Vepsitamab directs CD3-positive cells to target MUC17-positive cells. Vepsitamab induces cell activation and proliferation. Vepsitamab is applicable to research related to gastric cancer and gastroesophageal junction (g/gej) cancer .

HY-17021B

Esomeprazole potassium salt 2 Publications Verification (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research .

HY-B2089

Cinitapride	5-HT Receptor Dopamine Receptor	Neurological Disease Metabolic Disease
Cinitapride is a nonselective 5-HT1 and 5-HT4 receptors agonist and a 5-HT2 and D2 antagonist. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research .

HY-10061B

Lesogaberan hydrochloride AZD-3355 hydrochloride	GABA Receptor	Metabolic Disease
Lesogaberan (AZD-3355) hydrochloride is a potent and selective GABA_B receptor agonist with an EC₅₀ of 8.6 nM for human recombinant GABA_B receptor. The affinity (K_is) of Lesogaberan hydrochloride for rat GABA_B and GABA_A receptors, as measured by displacement of [ ³H]GABA binding in brain membranes: 5.1 nM and 1.4 μM, respectively. Lesogaberan hydrochloride inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action .

HY-13100

PF 03716556	Proton Pump	Metabolic Disease
PF 03716556 is a potent, selective, competitive and reversible acid pump (H ⁺,K ⁺-ATPase) antagonist with pIC₅₀s of 6.026, 6.038 and 6.009 for porcine, canine, and human recombinant gastric H ⁺,K ⁺-ATPase, respectively. PF 03716556 is inactive against other receptors, ion channels, and enzymes. PF 03716556 has the potential for gastroesophageal reflux disease research .

HY-100007A

Vonoprazan hydrochloride Maximum Cited Publications 6 Publications Verification TAK-438 hydrochloride	Proton Pump Bacterial	Infection Endocrinology Cancer
Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .

HY-W008614

Lansoprazole sulfone 1 Publications Verification AG-1813	Drug Metabolite Proton Pump	Metabolic Disease
Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H ⁺, K ⁺-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H ⁺, K ⁺-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-P991739

RC148	VEGFR PD-1/PD-L1	Cancer
RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1. RC148 blocks PD-1-PD-L1 and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer .

HY-17021A

Esomeprazole magnesium salt (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021R

Esomeprazole (Standard) (S)-Omeprazole (Standard); (-)-Omeprazole (Standard)	Reference Standards Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole (Standard) is the analytical standard of Esomeprazole. This product is intended for research and analytical applications. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-111313

JNJ-26070109	Cholecystokinin Receptor	Metabolic Disease
JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pK_is of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the research of gastroesophageal reflux disease .

HY-17021S1

Esomeprazole-d3 (S)-Omeprazole-d₃; (-)-Omeprazole-d₃	Isotope-Labeled Compounds Proton Pump	Inflammation/Immunology Endocrinology Cancer
Esomeprazole-d₃ is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0732A

Itopride HSR803 free base	Cholinesterase (ChE) Dopamine Receptor Bacterial	Others
Itopride (HSR803 free base) is a potent and orally active dopamine-2 antagonist and an acetylcholine esterase (AChE) inhibitor. Itopride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions, can be used as a gastrointestinal prokinetic agent. Itopride can be used for researching gastro-esophageal reflux disease (GERD) .

HY-B0656AS

Rabeprazole-d4 sodium LY307640-d4 sodium	Isotope-Labeled Compounds Proton Pump Apoptosis	Inflammation/Immunology Cancer
Rabeprazole-d₄ (sodium) is the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-15295R

Vonoprazan Fumarate (Standard) TAK-438 (Standard)	Proton Pump Reference Standards	Metabolic Disease Cancer
Vonoprazan (Fumarate) (Standard) is the analytical standard of Vonoprazan (Fumarate). This product is intended for research and analytical applications. Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-U00373

Revexepride 1 Publications Verification	5-HT Receptor Cytochrome P450	Neurological Disease
Revexepride is a highly selective 5-HT4 receptor agonist, and a potential inducer of CYP3A4 enzyme, used for the treatment of gastroesophageal reflux disease.

HY-17023R

Esomeprazole sodium (Standard) (S)-Omeprazole sodium (Standard); (-)-Omeprazole sodium (Standard)	Reference Standards Exosomes Proton Pump Bacterial	Endocrinology Cancer
Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium). This product is intended for research and analytical applications. Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B2089R

Cinitapride (Standard)	Reference Standards 5-HT Receptor Dopamine Receptor	Neurological Disease Metabolic Disease
Cinitapride (Standard) is the analytical standard of Cinitapride. This product is intended for research and analytical applications. Cinitapride is a nonselective 5-HT1 and 5-HT4 receptors agonist and a 5-HT2 and D2 antagonist. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research .

HY-B0656S

Rabeprazole-d4 LY307640-d₄	Isotope-Labeled Compounds Proton Pump Apoptosis	Inflammation/Immunology Cancer
Rabeprazole-d₄ is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-100007R

Vonoprazan (Standard) TAK-438 (Standard)	Reference Standards Proton Pump Bacterial	Endocrinology
Vonoprazan (Standard) is the analytical standard of Vonoprazan. This product is intended for research and analytical applications. Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .

HY-19865

Azeloprazole sodium	Proton Pump	Inflammation/Immunology
Azeloprazole sodium is a potent proton pump inhibitor (PPI). Azeloprazole sodium can be used for gastroesophageal reflux disease (GERD) research .

HY-110255

AZD 2066 1 Publications Verification	mGluR Calcium Channel Trk Receptor	Neurological Disease
AZD-2066 is a selective, orally active and blood-brain barrier-permeating mGluR5 antagonist. AZD 2066 activates the BDNF/trkB signaling pathway. AZD 2066 can be used in the research of neuropathic pain, major depressive disorder and gastroesophageal reflux disease .

HY-17023S

Esomeprazole-d6 sodium (S)-Omeprazole-d6 sodium; (-)-Omeprazole-d6 sodium	Isotope-Labeled Compounds Proton Pump	Others
Esomeprazole-d₆ sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-W008614S

Lansoprazole sulfone-d4 AG-1813-d₄	Isotope-Labeled Compounds Proton Pump Drug Metabolite	Inflammation/Immunology
Lansoprazole sulfone (AG-1813)-d₄ is the deuterium labeled Lansoprazole sulfone (HY-W008614). Lansoprazole sulfone, Lansoprazole (HY-13662) metabolite, is a H ⁺, K ⁺-ATPase inhibitor. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-B0656AR

Rabeprazole sodium (Standard) LY307640 sodium (Standard)	Reference Standards Proton Pump Apoptosis Bacterial	Inflammation/Immunology Cancer
Rabeprazole (sodium) (Standard) is the analytical standard of Rabeprazole (sodium). This product is intended for research and analytical applications. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-Z3421S

Vonoprazan-d3 fumarate	Isotope-Labeled Compounds	Others
Vonoprazan-d₃ fumarate is the deuterium labeled Vonoprazan fumarate (HY-15295). Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-10061

Lesogaberan AZD-3355	GABA Receptor	Metabolic Disease
Lesogaberan (AZD-3355) is a potent and selective GABA_B receptor agonist with an EC₅₀ of 8.6 nM for human recombinant GABA_B receptors. The affinity (K_is) of Lesogaberan for rat GABA_B and GABA_A receptors, as measured by displacement of [ ³H]GABA binding in brain membranes: 5.1 nM and 1.4 μM, respectively. Lesogaberan inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action .

HY-169833

BL 6341A	Histamine Receptor	Inflammation/Immunology
BL 6341A is an antagonist for histamine H2 receptor with K_i of 3.5-4.4 nM, that inhibits histamine-induced acid secretion and cAMP formation. BL 6341A can be used in research of gastric acid secretion related diseases, such as gastric ulcer or gastroesophageal reflux .

HY-114682A

Lenperone hydrochloride AHR 2277	Dopamine Receptor	Neurological Disease
Lenperone hydrochloride (AHR 2277) is an antipsychotic compound and a dopamine antagonist. Lenperone hydrochloride reduces gastroesophageal sphincter pressure of healthy dogs. Lenperone hydrochloride can be used for neurological disease research .

HY-17021C

Esomeprazole hemistrontium (S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021S2

Esomeprazole-d3 potassium (S)-Omeprazole-d3 potassium; (-)-Omeprazole-d3 potassium	Bacterial Proton Pump Isotope-Labeled Compounds	Inflammation/Immunology Endocrinology Cancer
Esomeprazole-d₃ potassium is deuterated labeled Esomeprazole (HY-17021). Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0377G

Famotidine (GMP) MK-208 (GMP)	Histamine Receptor	Inflammation/Immunology Cancer
Famotidine GMP (MK-208 GMP) is Famotidine (HY-B0377) produced in GMP guideline. Famotidine GMP is a competitive histamine H2-receptor antagonist, inhibits gastric secretion, activates the gastric mucosal defensive mechanisms. Famotidine GMP ameliorates peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD) in rats model .

HY-B0160R

Lafutidine (Standard) FRG-8813 (Standard)	Reference Standards Histamine Receptor	Metabolic Disease Endocrinology
Lafutidine (Standard) is the analytical standard of Lafutidine. This product is intended for research and analytical applications. Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H₂RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease .

HY-B0656AS2

Rabeprazole-d4 potassium LY307640-d4 potassium	Apoptosis Bacterial Proton Pump Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Rabeprazole-d₄ potassium is deuterated labeled Rabeprazole potassium. Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an b>IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

Cat. No.	Product Name	Target	Research Area

HY-P2269A

MAIT-203 acetate	Drug Derivative	Cancer
MAIT-203 acetate is a cyclopentyalanin-derived peptidomimetic, potently inhibits the interaction of adenomatous polyposis coli (APC) and Asef (RhoGEF4), but not APC-Sam68 or APC-striatin interactions. MAIT-203 acetate binds APC-ARM with a K_i value of 0.015 μM and aK_d value of 0.036 μM. MAIT-203 acetate significantly represses the migration and invasion of colorectal cancer cells .

HY-P2269

MAIT-203	Drug Derivative	Cancer
MAIT-203, a cyclopentyalanin-derived peptidomimetic, potently inhibits the interaction of adenomatous polyposis coli (APC) and Asef (RhoGEF4), but not APC-Sam68 or APC-striatin interactions. MAIT-203 binds APC-ARM with a K_i of 0.015 μM and a K_d of 0.036 μM. MAIT-203 significantly represses the migration and invasion of colorectal cancer cells.

Cat. No.	Product Name	Target	Research Area	Image

HY-P99437

Anbenitamab 1 Publications Verification KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .

HY-P991564

Arcotatug IBI-343 antibody; HB37A6; TAK-921 Antibody	ADC Antibody Claudin	Cancer
Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs .

HY-P99941

Retifanlimab INCMGA-00012; MGA-012	PD-1/PD-L1	Cancer
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .

HY-P99523

Vepsitamab AMG 199	CD3	Cancer
Vepsitamab (AMG 199) is a bispecific T-cell engager (HLE BiTE) that binds to MUC17 and CD3. Vepsitamab directs CD3-positive cells to target MUC17-positive cells. Vepsitamab induces cell activation and proliferation. Vepsitamab is applicable to research related to gastric cancer and gastroesophageal junction (g/gej) cancer .

HY-P991739

RC148	VEGFR PD-1/PD-L1	Cancer
RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1. RC148 blocks PD-1-PD-L1 and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer .

HY-P992167

AB011	Claudin	Cancer
AB011 is a recombinant humanized anti-CLDN18.2 IgG1 monoclonal antibody. AB011 exhibits synergistic effects with cytotoxic compounds in preclinical studies. AB011 can be used for research on advanced gastric/gastroesophageal junction adenocarcinoma and advanced pancreatic cancer .

Cat. No.	Product Name	Chemical Structure

HY-17021S1

Esomeprazole-d3
Esomeprazole-d₃ is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0656AS

Rabeprazole-d4 sodium

Rabeprazole-d₄ (sodium) is the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0656S

Rabeprazole-d4
Rabeprazole-d₄ is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-17023S

Esomeprazole-d6 sodium
Esomeprazole-d₆ sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-W008614S

Lansoprazole sulfone-d4
Lansoprazole sulfone (AG-1813)-d₄ is the deuterium labeled Lansoprazole sulfone (HY-W008614). Lansoprazole sulfone, Lansoprazole (HY-13662) metabolite, is a H ⁺, K ⁺-ATPase inhibitor. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-Z3421S

Vonoprazan-d3 fumarate

Vonoprazan-d₃ fumarate is the deuterium labeled Vonoprazan fumarate (HY-15295). Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-17021S2

Esomeprazole-d3 potassium
Esomeprazole-d₃ potassium is deuterated labeled Esomeprazole (HY-17021). Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0656AS2

Rabeprazole-d4 potassium

Rabeprazole-d₄ potassium is deuterated labeled Rabeprazole potassium. Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an b>IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0160S

Lafutidine-d10
Lafutidine-d₁₀ is deuterium labeled Lafutidine. Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H2RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease .

HY-17021S

Esomeprazole-d3 sodium
Esomeprazole-d₃ (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-W008614S1

Lansoprazole sulfone-13C6
Lansoprazole sulfone (AG-1813)- ¹³C₆ is ¹³C labeled Lansoprazole sulfone (HY-W008614). Lansoprazole sulfone, Lansoprazole (HY-13662) metabolite, is a H ⁺, K ⁺-ATPase inhibitor. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-B0656S1

Rabeprazole-13C,d3

Rabeprazole-13C,d3 is a deuterated labeled Rabeprazole . Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0656AS1

Rabeprazole-d3 sodium

Rabeprazole-d₃ sodium the deuterium labeled Rabeprazole sodium (HY-B0656A). Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an b>IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0656AS3

Rabeprazole-13C,d3 sodium

Rabeprazole- ¹³C,d₃ (sodium) (LY307640- ¹³C,d₃ (sodium)) is ¹³C labeled Rabeprazole (sodium). Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0732AS

Itopride-d6

Itopride-d₆ (HSR803-d₆ (free base)) is deuterium labeled Itopride. Itopride (HSR803 free base) is a potent and orally active dopamine-2 antagonist and an acetylcholine esterase (AChE) inhibitor. Itopride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions, can be used as a gastrointestinal prokinetic agent. Itopride can be used for researching gastro-esophageal reflux disease (GERD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: